BioPharmSignal logoBioPharmSignal

Biotech News

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Outlook (OTLK)OutlookFinancing

ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has entered into

Related news

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

OTLKOutlook2026-04-23 20:05 EST

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

PRQRProQR Therapeutics2026-06-25 10:35 EST

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

MGTXMeiraGTx2026-04-16 11:48 EST

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

OCGNOcugen2026-05-04 20:01 EST

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

IRIXIRIDEX2026-07-20 11:00 EST

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

HROWHarrow, Inc.2026-03-24 20:57 EST

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

HROWHarrow, Inc.2026-03-24 12:15 EST

Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

KPRXKiora Pharmaceuticals2026-04-07 11:00 EST

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

View all latest news

Outlook

Outlook Therapeutics is an ophthalmology company focused on retinal disease and anti-VEGF therapy delivery. Its story centers on whether it can create a differentiated eye-care franchise.

Recent company news

OTLKOutlook2026-08-06 12:45 EST

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

OTLKOutlook2026-07-24 18:40 EST

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

OTLKOutlook2026-06-16 12:02 EST

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

OTLKOutlook2026-06-01 12:46 EST

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Stock data

Close
0.97 USD
Market cap
120.89M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States